Monitorización del tratamiento antibiótico nebulizado en bronquiectasias no fibrosis quística colonizadas por pseudomonasaeruginosaestudio multicéntric

  1. B. Navas Bueno
  2. J.M. Vaquero Barrios 1
  3. F. Casas Maldonado 2
  4. A. Padilla Galo
  5. E. González-Moya Mondelo
  6. M Arenas Gordillo
  7. J.C. Bioque Rivera
  8. R. Jimeno Galván
  9. S. Cano Gomez 3
  10. J.L. López Campos Bodineau 3
  11. A. Valido Morales 4
  12. S. Merlos Navarro 5
  1. 1 UGC de Neumología, Hospital Universitario Reina Sofía
  2. 2 UGC de Neumología, Hospital Universitario San Cecilio.
  3. 3 Hospital Universitario Virgen del Rocío
    info

    Hospital Universitario Virgen del Rocío

    Sevilla, España

    ROR https://ror.org/04vfhnm78

  4. 4 Hospital Universitario Virgen Macarena
    info

    Hospital Universitario Virgen Macarena

    Sevilla, España

    ROR https://ror.org/016p83279

  5. 5 Hospital Universitario Virgen de las Nieves
    info

    Hospital Universitario Virgen de las Nieves

    Granada, España

    ROR https://ror.org/02f01mz90

Show affiliations +
Journal:
Revista española de patología torácica

ISSN: 1889-7347

Year of publication: 2016

Volume: 28

Issue: 1

Pages: 9-15

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista española de patología torácica

Abstract

Objective: 1) Assess adherence to nebulized treatment with colistimethate sodium-Promixin® using an Ineb® nebulizer in patients with bronchiectasis (BQ)but without cystic fibrosis (CF) colonized by Pseudomonas aeruginosa; 2) Identify a noncompliant patient profile. Method: A multi-center, observational, prospective, transversal study, with a cohort of adults treatedfor at least six months with colistimethate sodium (Promixin®) administered with an Ineb® nebulizer. Registers of nebulized treatment were obtained (Insight® IT platform), pulmonary lung function, sputum culture and number of exacerbations prior to and after the treatment. Global adherence was analyzed, as well as handling the nebulizer and real adherence. Patients with poor therapeutic adherence were defined as those with a global or real adherence of ≤80%. Results: The initial sample included 126 patients, 20 of which were considered not valid for the analysis; 106 patients with BQ non-CF, 47 were post-infectious causes(44.3%), 13 COPD (12.3%), 12 ciliary dyskinesia(11.3%), 17 other causes (16%) and 17 idiopathic (16%). The mean age was 64.0 ± 14.6 years; 57 males (53.8%) and 49 females (46.2%), 61 were from tertiary hospitals (57.5%) and 45 from local hospitals (42.5%). Global adherence was 86.7 ± 19.3% and in 73.6% of the cases ≥80%. 96.6 ± 7.8% of the patients adequately handled the nebulizer, with nebulization times of 6.3 ± 3.4 minutes. Real adherence was 84.4 ± 20.2% and in 75.5% of the cases ≥80%. No differences were seen in terms of sex, age, pulmonary function, cause of BQ non-CFand prior exacerbationsfor none of these variables. Conclusion: In our population, handling the nebulizer and adherence, both global and real, is very good. The limited number of patients who failed to adhere has hindered our defining a non-compliant profile.

Data source: Dialnet